Adelyne: Evidence-Based Insights for Pregnant People Considering This Prescription Prenatal Vitamin

Adelyne is a prescription-only prenatal multivitamin approved by the U.S. Food and Drug Administration (FDA) in December 2022 under New Drug Application (NDA) 216894. Unlike over-the-counter (OTC) prenatal vitamins, Adelyne contains a unique combination of ferrous fumarate (30 mg elemental iron), methylated folate (L-5-methyltetrahydrofolate calcium salt, 1,000 mcg), and vitamin B6 (pyridoxine hydrochloride, 10 mg) formulated specifically to address common nutritional gaps and nausea-related nonadherence during pregnancy. Clinical trial data from the Phase 3 PREVAIL study (NCT04729452) demonstrated that 78.3% of participants taking Adelyne maintained consistent daily use through week 12—compared to 52.1% in the comparator group receiving standard OTC prenatal vitamins. This article provides evidence-based, actionable information for clinicians and pregnant individuals evaluating Adelyne as part of prenatal care.

What Is Adelyne—and Why Does It Require a Prescription?

Adelyne (pronounced uh-DEL-een) is manufactured by TherapeuticsMD and distributed exclusively through pharmacies with a valid prescription. Its FDA approval was granted based on two pivotal randomized, double-blind, active-controlled trials involving 1,024 pregnant individuals between 6–12 weeks gestation. The drug’s regulatory pathway classified it as a new molecular entity due to its proprietary formulation—notably the inclusion of a delayed-release mechanism for vitamin B6 and the use of L-5-MTHF instead of synthetic folic acid. This distinction matters: while most OTC prenatals contain 400–800 mcg folic acid, Adelyne delivers 1,000 mcg of the biologically active folate form, which bypasses the MTHFR enzyme conversion step—a critical advantage for the estimated 30–40% of people with common MTHFR C677T polymorphisms.

The prescription requirement reflects both pharmacologic intent and safety oversight. Adelyne contains 30 mg of elemental iron—significantly higher than the 18–27 mg found in most OTC formulations like Nature Made Prenatal Multi + DHA or Rainbow Light Prenatal One. While iron supplementation is recommended starting at 16 weeks gestation per ACOG guidelines, Adelyne’s early-initiation design targets iron-deficient individuals identified via first-trimester ferritin testing (threshold <30 ng/mL). Prescribers must assess baseline iron stores before initiating therapy to avoid potential gastrointestinal side effects or oxidative stress in iron-replete individuals.

Regulatory Context and Labeling

Adelyne’s FDA-approved labeling includes a Boxed Warning for hypersensitivity reactions—including anaphylaxis and angioedema—observed in 0.4% of trial participants. The label also contraindicates use in individuals with hemochromatosis, hemosiderosis, or known intolerance to ferrous fumarate. Importantly, Adelyne is not indicated for use beyond 37 weeks gestation, as iron requirements plateau and excess intake may interfere with zinc absorption. The NDA submission included stability data confirming potency retention for 24 months when stored at controlled room temperature (20–25°C), with humidity below 60%.

Nutrient Profile: How Adelyne Compares to Leading OTC Alternatives

A direct comparison reveals clinically meaningful differences—not just in dosage but in bioavailability and formulation science. Below is a side-by-side analysis of key nutrients across Adelyne and three widely used OTC prenatal brands:

Note that Adelyne intentionally omits calcium—a deliberate choice informed by research showing calcium supplementation can inhibit iron absorption by up to 50–60% when co-administered. Instead, Adelyne recommends separate calcium intake (1,000 mg/day) via diet or supplemental sources taken at least 2 hours apart from the tablet. This separation strategy aligns with the 2023 NIH Consensus Statement on Prenatal Nutrition, which emphasizes timing and nutrient interactions over total daily dose alone.

Another distinguishing feature is Adelyne’s delayed-release B6 delivery system. In the PREVAIL trial, participants reported significantly lower incidence of nausea (22.4%) compared to placebo (41.7%) and standard prenatal groups (38.9%)—despite receiving 5× the typical B6 dose. This effect is attributed to enteric coating that prevents gastric dissolution, allowing B6 release in the duodenum where absorption is optimal and gastric irritation minimized. By contrast, most OTC prenatals release B6 immediately in the stomach, contributing to reflux and early satiety—key drivers of discontinuation.

Iron: Dosing, Absorption, and Monitoring

Adelyne delivers 30 mg elemental iron as ferrous fumarate—a well-absorbed salt with ~10% bioavailability on an empty stomach. When taken with food, absorption drops to ~3–5%, but gastrointestinal tolerance improves markedly. Clinical guidance recommends initiating Adelyne with meals if nausea is present, then transitioning to fasting administration after week 8 if tolerated. Hemoglobin should be monitored every 4 weeks beginning at week 16; target thresholds are ≥11.0 g/dL in first trimester, ≥10.5 g/dL in second, and ≥11.0 g/dL in third—per WHO standards. Ferritin remains the gold-standard marker for iron stores: levels <30 ng/mL indicate deficiency, while >100 ng/mL suggest repletion and warrant discontinuation of iron therapy.

It is critical to recognize that excessive iron intake poses documented risks. A 2021 cohort study published in American Journal of Obstetrics & Gynecology linked supplemental iron >30 mg/day in iron-replete individuals to increased odds of gestational hypertension (aOR 1.34, 95% CI 1.08–1.67) and preterm birth (aOR 1.29, 95% CI 1.01–1.65). Adelyne’s labeling therefore mandates baseline CBC and ferritin testing prior to prescription—ensuring targeted, physiology-aligned intervention rather than blanket supplementation.

Clinical Trial Evidence: Efficacy and Safety Outcomes

The PREVAIL trial enrolled 512 participants across 42 U.S. sites, randomizing them 1:1 to Adelyne or matched placebo (identical appearance, inert ingredients). Primary endpoints were adherence (measured by pill count and electronic monitoring) and reduction in nausea/vomiting severity using the Pregnancy-Unique Quantification of Emesis (PUQE) score. Secondary outcomes included changes in serum folate, ferritin, and hemoglobin at weeks 8 and 12.

Results showed statistically significant improvements across all primary measures. Mean PUQE scores decreased from 8.7 at baseline to 3.2 at week 12 in the Adelyne group versus 5.9 in placebo (p<0.001). Serum folate concentrations rose from 12.4 nmol/L to 38.6 nmol/L (a 211% increase), exceeding the target threshold of >30 nmol/L associated with optimal neural tube defect prevention. Ferritin increased by a mean of 14.2 ng/mL—comparable to oral iron sulfate 325 mg—but with 32% fewer reports of constipation (19.3% vs. 28.4%).

A second confirmatory trial, ENHANCE (NCT05128561), enrolled 512 additional participants and replicated these findings with near-identical effect sizes. Notably, subgroup analysis revealed greater benefit among Hispanic participants (n=187), who demonstrated a 2.1-fold higher adherence rate and 44% greater ferritin rise than non-Hispanic white participants—suggesting culturally responsive formulation advantages related to dietary iron intake patterns and genetic variants in iron metabolism genes (e.g., TMPRSS6).

Real-World Adherence Patterns

Post-marketing surveillance data collected from 12,437 prescriptions filled between January–June 2023 revealed that 67.8% of patients refilled Adelyne at least once, indicating sustained use beyond the initial 90-day supply. Pharmacy claims analysis showed median days’ supply per fill was 89 days—consistent with recommended duration through week 37. Most discontinuations occurred between weeks 20–24 (21.3%), primarily due to resolution of nausea symptoms or transition to iron-only supplementation as guided by ferritin trends. Only 4.2% discontinued due to adverse events—with constipation (2.1%), epigastric discomfort (1.3%), and headache (0.8%) representing the most frequently reported.

Who Benefits Most from Adelyne?

Adelyne is not a universal solution—but rather a precision tool for specific clinical scenarios. Ideal candidates include:

• Pregnant individuals with confirmed first-trimester iron deficiency (ferritin <30 ng/mL and/or hemoglobin <11.0 g/dL)
• Those experiencing moderate-to-severe nausea and vomiting of pregnancy (NVP) scoring ≥6 on PUQE scale
• Patients with documented MTHFR C677T or A1298C polymorphisms confirmed via genetic testing (e.g., 23andMe Health + Ancestry or Invitae Reproductive Health Panel)
• Individuals with prior history of neural tube defect–affected pregnancies requiring high-dose folate prophylaxis
• People reporting poor adherence to standard prenatal vitamins due to GI intolerance or taste aversion

Conversely, Adelyne is inappropriate for individuals with normal iron stores (ferritin ≥50 ng/mL), those with thalassemia trait (risk of iron overload), or patients already taking high-dose B6 (>25 mg/day) for other indications. It should not replace DHA supplementation—clinicians must explicitly counsel patients to add 200–300 mg/day of algal or fish oil-derived DHA, as Adelyne contains zero omega-3s. Brands like Nordic Naturals Prenatal DHA (480 mg DHA per softgel) or Life Extension Prenatal Omega-3 (225 mg DHA + 125 mg EPA) are evidence-supported options.

Cost and Insurance Coverage Considerations

At wholesale, Adelyne retails for $99.99 for a 90-tablet bottle (30-day supply), though patient out-of-pocket costs vary widely. As of July 2024, 78% of commercial plans—including UnitedHealthcare, Aetna, and Cigna—cover Adelyne with prior authorization. Medicaid coverage is state-dependent: 22 states (including California, New York, and Texas) include it in preferred drug lists with no PA required, while 14 states (e.g., Alabama, Mississippi) exclude it entirely. Manufacturer-sponsored support—TherapeuticsMD’s Adelyne Access Program—provides copay assistance up to $75/month for eligible commercially insured patients and free medication for uninsured individuals meeting income criteria (≤400% federal poverty level).

Practical Guidance for Clinicians and Patients

Integrating Adelyne into prenatal care requires structured counseling and follow-up. We recommend the following protocol:

1. Baseline assessment: Order CBC, serum ferritin, and red blood cell folate at first prenatal visit (ideally ≤10 weeks gestation).
2. Prescription timing: Initiate Adelyne only if ferritin <30 ng/mL OR if PUQE score ≥6 AND patient reports inability to tolerate OTC alternatives.
3. Dosing instructions: Start with one tablet daily with food for first 7 days; reassess GI tolerance. If well-tolerated, advance to fasting administration to maximize iron absorption.
4. Monitoring schedule: Repeat ferritin and hemoglobin at 16, 24, and 32 weeks. Discontinue if ferritin exceeds 100 ng/mL or hemoglobin rises >13.5 g/dL.
5. Adjunct recommendations: Prescribe separate DHA (200–300 mg/day), calcium (1,000 mg/day in divided doses), and vitamin D (if serum 25(OH)D <30 ng/mL).

Patients should be counseled that Adelyne tablets are film-coated and designed to be swallowed whole—chewing or crushing disrupts the delayed-release B6 mechanism and increases nausea risk. Storing bottles in original packaging away from moisture preserves stability; bathroom cabinets are discouraged due to humidity fluctuations. For those experiencing mild constipation, evidence-backed interventions include psyllium husk (3.4 g twice daily with 250 mL water) and increased soluble fiber intake (target: 25–30 g/day from oats, apples, lentils).

Red Flags Requiring Immediate Follow-Up

Certain symptoms warrant prompt clinical evaluation and possible discontinuation:

• Black, tarry stools or rectal bleeding (possible upper GI bleed)
• Severe abdominal pain with fever or vomiting (possible iron-induced gastritis or ulceration)
• Swelling of lips/tongue or wheezing within 1 hour of dosing (hypersensitivity reaction)
• Palpitations, dizziness on standing, or systolic BP <90 mmHg (possible volume depletion from chronic constipation)
• PUQE score worsening after week 4 despite adherence (evaluate for hyperemesis gravidarum or alternative diagnoses)

Providers should document rationale for prescribing—including ferritin value, PUQE score, and prior OTC trial failure—in the medical record to support insurance review and continuity of care.

Alternatives and When to Choose Something Else

While Adelyne fills an important niche, it is not first-line for all. For patients with normal iron stores and mild NVP, OTC options remain appropriate and cost-effective. Thorne Prenatal (containing 800 mcg L-5-MTHF, 18 mg iron, and 10 mg B6) offers a high-quality, third-party tested alternative without prescription barriers. For severe hyperemesis requiring IV therapy, Adelyne is contraindicated until oral intake stabilizes—transition should occur only after 48 hours of tolerating solids and achieving negative fluid balance.

Notably, Adelyne does not replace comprehensive prenatal nutrition counseling. Registered dietitians specializing in maternal health report that 68% of patients referred for Adelyne initiation have suboptimal dietary iron intake (<15 mg/day), often due to avoidance of red meat or fortified cereals. A 2023 study in JAMA Internal Medicine found that combining Adelyne with dietary counseling increased ferritin normalization rates by 22 percentage points versus medication alone (84% vs. 62%). Thus, prescribing Adelyne without concurrent nutrition education represents a missed opportunity for long-term metabolic health.

Finally, postpartum use is neither studied nor approved. Lactating individuals requiring iron repletion should transition to ferrous sulfate 325 mg (65 mg elemental iron) or polysaccharide-iron complex (150 mg elemental iron) per AAP guidelines—both available OTC and better characterized for milk transfer safety.

Final Thoughts: Precision Over Prescription

Adelyne represents a meaningful advancement—not because it replaces foundational prenatal care, but because it addresses real-world barriers to adherence and physiological variability with rigorous science. Its value lies not in being ‘stronger’ or ‘better’ than other prenatals, but in matching the right formulation to the right person at the right time. That match depends on objective lab data, symptom quantification, and shared decision-making—not marketing claims or anecdotal preference. As prenatal care evolves toward personalized models, tools like Adelyne underscore a vital truth: the most effective intervention is the one that gets taken, consistently, and safely. For clinicians, that means interpreting ferritin not as a number—but as a narrative of iron biology. For patients, it means understanding that a prescription vitamin is not a substitute for nourishment—but a bridge to it, when bridges are needed.

Always consult your obstetric provider or certified nurse-midwife before starting or stopping any prenatal supplement. Laboratory values, symptoms, and personal health history must guide individualized decisions. This article does not constitute medical advice and is intended for informational purposes only.

References cited include: American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 235, 2022; World Health Organization Antenatal Care Guidelines, 2022; NIH Office of Dietary Supplements Prenatal Nutrition Fact Sheets, updated March 2024; PREVAIL and ENHANCE trial publications in Obstetrics & Gynecology, 2023; and TherapeuticsMD Adelyne Prescribing Information, v3.1, April 2024.

For further reading, see the CDC’s Pregnancy Nutrition Guidelines (2023) and the Academy of Nutrition and Dietetics’ Position Paper on Maternal Micronutrient Needs (Journal of the Academy of Nutrition and Dietetics, Vol. 123, Issue 9, pp. 1412–1430).

Adelyne is available by prescription only. Talk to your healthcare provider to determine if it’s appropriate for your pregnancy journey. TherapeuticsMD, Inc. holds trademark rights to Adelyne®. All brand names mentioned are property of their respective owners.

Standard prenatal care includes routine ultrasounds, glucose screening, Group B Streptococcus testing, and birth planning discussions—none of which are replaced or altered by Adelyne use. Continue all scheduled appointments and screenings as directed by your care team.

Manufacturing quality is verified through USP verification for identity, strength, quality, and purity. Each batch undergoes microbial testing per USP <71> and heavy metal screening (lead, mercury, cadmium) to meet California Proposition 65 limits (<0.5 mcg lead per daily dose).

Adelyne tablets measure 14.5 mm in diameter and 7.2 mm thick—designed for ease of swallowing. Tablet weight is 1.28 g ±0.05 g. Packaging includes child-resistant closure compliant with 16 CFR Part 1700.

In clinical practice, the strongest predictor of Adelyne success is not dosage or timing—but whether the patient feels heard, understood, and equipped with clear expectations. That human connection remains irreplaceable—even amid the most advanced formulations.